Therapy: Immunogenicity of biologic therapies-we need tolerance

Nature Reviews Rheumatology

Volumn 6, Issue 10, 2010, Pages 558-559

  Krieckaert, Charlotte L M ^a   Bartelds, G Margret ^a   Wolbink, Gerrit Jan ^a  

^a JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; EPITOPE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ADD ON THERAPY; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CROHN DISEASE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; T CELL LYMPHOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MICE; PROTEIN BINDING;

EID: 77957594345     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.153     Document Type: Short Survey

References (10)

1. Wolbink, G. J., Aarden, L. A. & Dijkmans, B. A. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr. Opin. Rheumatol. 21, 211-215 (2009).
2. Baert, F. et al. influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601-608 (2003). (Pubitemid 36204954)
3. Bartelds, G. M. et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66, 921-926 (2007).
4. Somerfield, J. et al. A novel strategy to reduce the immunogenicity of biological therapies. J. Immunol. 185, 763-768 (2010)
5. Weinblatt, M. E. et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum. 38, 1589-1594 (1995).
6. Coles, A. J. et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786-1801 (2008).
7. Gilliland, L. K. et al. elimination of the mmunogenicity of therapeutic antibodies. J. Immunol. 162, 3663-3671 (1999).
8. Maini, R. N. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552-1563 (1998).
9. Colombel, J. F. et al. infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383-1395 (2010).
10. Parker, A. S., Zheng, W., Griswold, K. E. & Bailey-Kellogg, C. Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinformatics 11, 180 (2010).